Project cooperation
SSO-001 for Osteoarthritis (OA)
SSO-001 may act as a disease-modifying drug and relieves OA associated symptoms, completed Phase IIa clinical study.
- Research
- Execution
- Technical
- Financing
- Sales/Distribution
SANSHO Co., Ltd. is a biotech venture company operating in three business areas: pharmaceuticals, cosmetics, and food, leveraging its core technology of cyclic phosphatidic acid (cPA), a result of research at Ochanomizu University.
In its core pharmaceutical business, SANSHO is building multiple pipelines by leveraging cPA's unique mechanisms of action, including anti-inflammatory, tissue regenerative, and anti-fibrotic properties. One such pipeline, SSO-001, is a new compound with the potential to promote cartilage regeneration and is currently progressing smoothly in clinical trials overseas.
Other pipelines in the development stage include SSI-002, a drug for idiopathic pulmonary fibrosis, and SSG-003, a drug for glaucoma.
SANSHO also sells cPA as a cosmetic and food ingredient. The products developed using technology cultivated through pharmaceutical development have received a certain level of recognition in the market, and the company is working to further expand its business.
Business Domain / 分野
Business Type / 業種
Disease Area / 疾患領域
Modalities / モダリティ
Additional questions
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術
Project cooperation
SSO-001 for Osteoarthritis (OA)
SSO-001 may act as a disease-modifying drug and relieves OA associated symptoms, completed Phase IIa clinical study.
Project cooperation
SSI-002 for Idiopathic Pulmonary Fibrosis (IPF)
SSI-002 is a promising therapeutic candidate for pulmonary fibrosis, planned Phase I clinical study in 2026.
Project cooperation
SSD-004 for Systemic Scleroderma (SSc)
SSD-004 could be a novel strategy for the treatment of SSc.
Project cooperation
SSH-005 for Hypotrichosis (congenital lack of hair)
SSH-005 has potential for use in congenital hypotrichosis.
Project cooperation
SSG-003 offers a new approach to glaucoma treatment.